Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devasting consequences on treatment and prevention programmes, including for HIV and TB across the globe. Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like.
About the speaker:
Mitchell Warren has spent nearly 30 years devoted to expanding access to HIV prevention, working with a wide range of activists and advocates, researchers and scientists, product developers and deliverers, policy makers, community advisory boards and the media from across the globe. This has often been as a translator, helping these often-diverse groups with diverse points of view understand each other better.
Since 2004, Mitchell has been the Executive Director of AVAC, an international non-governmental organization that works to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive and integrated pathway to global health equity. Through communications, education, policy analysis, advocacy and a network of global collaborations, it mobilizes and supports efforts to deliver proven HIV prevention tools for immediate impact, demonstrates and rolls out new HIV prevention options, and develops long-term solutions needed to end the epidemic.
All content for Translational Health Sciences is the property of Oxford University and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devasting consequences on treatment and prevention programmes, including for HIV and TB across the globe. Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like.
About the speaker:
Mitchell Warren has spent nearly 30 years devoted to expanding access to HIV prevention, working with a wide range of activists and advocates, researchers and scientists, product developers and deliverers, policy makers, community advisory boards and the media from across the globe. This has often been as a translator, helping these often-diverse groups with diverse points of view understand each other better.
Since 2004, Mitchell has been the Executive Director of AVAC, an international non-governmental organization that works to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive and integrated pathway to global health equity. Through communications, education, policy analysis, advocacy and a network of global collaborations, it mobilizes and supports efforts to deliver proven HIV prevention tools for immediate impact, demonstrates and rolls out new HIV prevention options, and develops long-term solutions needed to end the epidemic.
Why digital health and care interventions fail and what we can do about it
Translational Health Sciences
48 minutes
1 year ago
Why digital health and care interventions fail and what we can do about it
Unfortunately, many digital health interventions fail to realize their potential. Although there is no recipe for success, there are ways in which developers, implementers, and adopters can help to maximize successful implementation, adoption, and scaling Unfortunately, many digital health interventions fail to realize their potential. Although there is no recipe for success, there are ways in which developers, implementers, and adopters can help to maximize successful implementation, adoption, and scaling.
Translational Health Sciences
Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devasting consequences on treatment and prevention programmes, including for HIV and TB across the globe. Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like.
About the speaker:
Mitchell Warren has spent nearly 30 years devoted to expanding access to HIV prevention, working with a wide range of activists and advocates, researchers and scientists, product developers and deliverers, policy makers, community advisory boards and the media from across the globe. This has often been as a translator, helping these often-diverse groups with diverse points of view understand each other better.
Since 2004, Mitchell has been the Executive Director of AVAC, an international non-governmental organization that works to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive and integrated pathway to global health equity. Through communications, education, policy analysis, advocacy and a network of global collaborations, it mobilizes and supports efforts to deliver proven HIV prevention tools for immediate impact, demonstrates and rolls out new HIV prevention options, and develops long-term solutions needed to end the epidemic.
